According to our results, MTF1 expression was discrepant in different immune subtypes of nine cancers, and in tumors including BLCA, BRCA, KIRC, PRAD, and SKCM, MTF1 expression was higher in C2 (IFN-γ dominant) or C3 (inflammatory) and lower in C6 (TGF-β) subtype, which was consistent with previous findings 38. This evidence concerns the gene TGFB1 and cancer.